Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. develops clinical-stage treatments for rare diseases and diseases with high unmet need, with news centered on anti-infective programs for multi-drug resistant bacterial infections. Updates frequently cover tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, and its licensed development and commercialization relationship with GSK outside certain Asian territories.
Company announcements also report quarterly and annual operating results, business updates, clinical data presentations, FDA submission activity, portfolio-expansion efforts, cash runway commentary, and equity-compensation grants under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Spero Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. Management will present from 10:30 AM to 11:00 AM ET and is available for one-on-one meetings. Key products include SPR720, targeting non-tuberculous mycobacterial infections, and Tebipenem HBr, an investigational drug for complicated urinary tract infections (cUTI). Spero is also developing SPR206, an IV-administered candidate for multi-drug resistant Gram-negative infections. Investors can access the webcast through the Spero website after the event. The company focuses on addressing rare diseases and multi-drug resistant bacterial infections with promising therapies.
Spero Therapeutics (Nasdaq: SPRO) announced two poster presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The presentations, both authored by RE Mendes, Ph.D., focus on the in vitro activity of SPR206 against bacterial infections, highlighting its potential against Enterobacterales and Pseudomonas aeruginosa isolates in Europe. These studies underscore Spero's commitment to addressing multi-drug resistant (MDR) infections and developing effective treatments. The research was sponsored by Spero and supported by the Office of the Assistant Secretary of Defense for Health Affairs. For more details, visit Spero's official site for key publications and presentations.